Physician to Discuss “Sudden Cardiac Arrest” in Weslaco Feb. 7

Breaking News
264

Translate to Spanish or other 102 languages!

 Mega Doctor News

- Advertisement -

Weslaco –  Dr. Robert Sepulveda, Internal Medicine Physician, will speak and answer questions on “Sudden Cardiac Arrest: What to Do?”  during a free “Senior Health Talk” for the community on Tuesday, February 7 at 12:30 p.m. at the Knapp Conference Center, located in the 700 block of Knapp Medical Boulevard on the west side of the hospital in Weslaco.    For more information, please call (956) 973-5142.

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Doctors Hospital at Renaissance’s 3rd Annual Obesity and Diabetes Summit Set for February 24TH – 25TH, 2017
Next article
Valley Baptist Legacy Foundation announces $15M gift to benefit UTRGV Institute for Neurosciences

More Articles

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.

Texas Oncology Expands Cancer Care With New McAllen West Clinic

Texas Oncology celebrated the grand opening of its McAllen West clinic Sept. 29, expanding cancer treatment, diagnostic, and research capabilities in the Rio Grande Valley as the organization continues its presence in the region, spanning more than 40 years.

Multicancer Blood Test Detects 17 Cancer Types in Large Prospective Study

A large prospective study published in Nature Medicine found that a blood test designed to detect multiple cancers identified cancer signals across 17 broad cancer types, such as ovarian, lung, breast and colorectal cancers, and many which do not have recommended screening tests.

Pancreatic Cancer Patients Gain Early Access to Experimental Drug Daraxonrasib Following Fast-Track FDA Decision

The U.S. Food and Drug Administration is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.
- Advertisement -